.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Teva
US Department of Justice
AstraZeneca
Federal Trade Commission
Mallinckrodt
Covington
UBS
Johnson and Johnson
Cantor Fitzgerald

Generated: September 26, 2017

DrugPatentWatch Database Preview

RANEXA Drug Profile

« Back to Dashboard

What is the patent landscape for Ranexa, and when can generic versions of Ranexa launch?

Ranexa is a drug marketed by Gilead and is included in one NDA. There are ten patents protecting this drug.

This drug has ninety-two patent family members in twenty-nine countries.

The generic ingredient in RANEXA is ranolazine. There are fifteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ranolazine profile page.

Summary for Tradename: RANEXA

Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list78
Clinical Trials: see list10
Patent Applications: see list829
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RANEXA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► SubscribeY ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RANEXA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007► Subscribe► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RANEXA

Country Document Number Estimated Expiration
Australia2001240092► Subscribe
Norway20024270► Subscribe
Denmark1096937► Subscribe
Japan4108980► Subscribe
Japan2003525896► Subscribe
Norway320986► Subscribe
Georgia, Republic ofP20043289► Subscribe
World Intellectual Property Organization (WIPO)0166093► Subscribe
Poland357273► Subscribe
European Patent Office1263439► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RANEXA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/058United Kingdom► SubscribePRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 - 006 20080714
1/2009Austria► SubscribePRODUCT NAME: RANOLAZIN ODER EIN SALZ ODER SOLVAT DAVON
0371Netherlands► SubscribePRODUCT NAME: RANOLAZINE OF EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714
C0001France► SubscribePRODUCT NAME: RANOLAZINE OU L?UN DE SES SELS OU L?UN DE SES SOLVATES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/462/001 DU 20080709; REGISTRATION NO/DATE AT EEC: EU/1/08/462/001-006 DU 20080709
2008017Lithuania► SubscribePRODUCT NAME: RANOLAZINUM; REGISTRATION NO/DATE: EU/1/08/462/001 - EU/1/08/462/006 20080709
08/034Ireland► SubscribePRODUCT NAME: RANOLAZINE OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 20080709
504Luxembourg► Subscribe91504, EXPIRES: 20230709
1Finland► Subscribe
2008000065Germany► SubscribePRODUCT NAME: RANOLAZIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080709
1109558/01Switzerland► SubscribePRODUCT NAME: RANOLAZINE; REGISTRATION NO/DATE: SWISSMEDIC 60553 13.04.2010
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Federal Trade Commission
US Department of Justice
Teva
Cerilliant
Chinese Patent Office
Baxter
Julphar
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot